Featured Research

from universities, journals, and other organizations

A tiny channel and a large vessel: a new clue for heart attack

Date:
September 9, 2013
Source:
Manchester University
Summary:
Scientists have identified a gene variant that predisposes people to a special type of heart attack. This research could lead to the development of new drugs to treat the problem.

Scientists at The University of Manchester and medical institutes in Italy have identified a gene variant that predisposes people to a special type of heart attack.

Their research, published in the International Journal of Cardiology could lead to the development of new drugs to treat the problem.

Dr Paolo Tammaro, who led the team, said: "Heart attacks happen when the blood supply to the heart is reduced by the narrowing or blocking of the coronary artery -- the vessel that supplies the heart with oxygen and nutrients. Often this is due to fatty deposits which narrow the vessel. However, in some people with perfectly clean arteries, the vessel suddenly constricts shutting off the blood supply. We have discovered that this process, known as vasospasm, can be associated with a rare variant of a particular gene."

Dr Enzo Emanuele, from the University of Pavia, who screened the patients, said: "We knew that this type of heart attack occurs in about 6% of patients and that many of them have a genetic predisposition, but we did not know the gene responsible. Now that it is identified it will be possible to predict who is at risk and to treat them accordingly."

The gene identified by the team encodes a protein termed KATP channel. This protein forms microscopic gated pores that allow potassium ions to move into and out of the cells, in this way giving rise to electrical impulses.

Dr Tammaro and research scientist Keith Smith, both based at the Faculty of Life Sciences at The University of Manchester, added: "These channels are abundant in the cells forming the wall of coronary arteries, and the electrical impulses they generate govern this artery's diameter. Due to the mutation we have identified, the KATP channel in the coronary artery can no longer fulfill this delicate process."

The team, whose work was supported by the BBSRC (Biotechnology and Biological Sciences Research Council), now plans to approach pharmaceutical companies with their findings, aiming to design novel drugs that could interact with this new target.


Story Source:

The above story is based on materials provided by Manchester University. Note: Materials may be edited for content and length.


Journal Reference:

  1. Keith J. Smith, Andrew J. Chadburn, Aiste Adomaviciene, Piercarlo Minoretti, Luigi Vignali, Enzo Emanuele, Paolo Tammaro. Coronary spasm and acute myocardial infarction due to a mutation (V734I) in the nucleotide binding domain 1 of ABCC9. International Journal of Cardiology, 2013; DOI: 10.1016/j.ijcard.2013.04.210

Cite This Page:

Manchester University. "A tiny channel and a large vessel: a new clue for heart attack." ScienceDaily. ScienceDaily, 9 September 2013. <www.sciencedaily.com/releases/2013/09/130909105223.htm>.
Manchester University. (2013, September 9). A tiny channel and a large vessel: a new clue for heart attack. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2013/09/130909105223.htm
Manchester University. "A tiny channel and a large vessel: a new clue for heart attack." ScienceDaily. www.sciencedaily.com/releases/2013/09/130909105223.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins